Investigating how reducing Glut1 can prevent diabetes-related complications
Official title: Glut1 and the microvascular complications of diabetes
Funded at Louis Stokes Cleveland VA Medical Center · NIH-11098449 · Data updated 2026-11-12
This study is looking at whether reducing a protein called Glut1 can help prevent serious problems that can happen with diabetes, like eye, kidney, and nerve issues, using mice with both Type 1 and Type 2 diabetes to find better ways to manage the condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Louis Stokes Cleveland VA Medical Center NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | January 1, 2022 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| NIH project number | 5I01BX005844-04 |
| Project ID | NIH-11098449 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with Type 1 or Type 2 diabetes who are at risk for microvascular complications.
✕Less likely to help
Patients without diabetes or those who do not have risk factors for microvascular complications may not benefit from this research.
What this research studies
This research aims to explore whether lowering the levels of the glucose transporter Glut1 can help prevent serious complications associated with diabetes, such as diabetic retinopathy, kidney disease, and peripheral neuropathy. The study will utilize mouse models of both Type 1 and Type 2 diabetes to assess the effects of Glut1 reduction through genetic and pharmacological methods. By understanding the role of Glut1 in these complications, the research seeks to identify new strategies to improve diabetes management and patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce the risk of severe complications in diabetes patients.
How similar studies have gone: Previous research has shown promising results in targeting Glut1 for preventing diabetic complications, indicating potential for success in this approach.
Where this research is happening
-
Louis Stokes Cleveland VA Medical Center
Cleveland, United States Active
Researchers
- Principal investigator: Samuels, Ivy S — Louis Stokes Cleveland VA Medical Center
- Study coordinator: Samuels, Ivy S
Related research
Other NIH-funded projects on the same topics.
-
HEARTS hypertension and diabetes care in Guatemala
This grant tests how well the HEARTS primary care model works in Guatemala to improve blood pressure and blood sugar control for patients.
-
Retinal signals in early diabetes and how they affect vision
This grant looks at how diabetes changes the signals in the retina that control vision, with a focus on inner retinal cells and how these changes may lead to vision problems.
-
Integrated Heart Health: A HEARTS-based approach to hypertension and diabetes in Guatemala
A study tests a team-based, stepwise care model to improve blood pressure and blood sugar control for people with both hypertension and diabetes in Guatemala.
-
Bringing WHO HEARTS-D diabetes care into Bangladesh cities
A program to help urban clinics in Bangladesh adopt WHO HEARTS-D guidelines to improve detection, treatment, and control of type 2 diabetes.
-
AI-powered fundus imaging to screen for type 2 diabetes
A mobile AI tool uses eye images to help screen adults for type 2 diabetes in clinics or communities.
-
AI-powered eye imaging to screen for type 2 diabetes with a mobile phone
A plan to use AI on smartphone retinal images to help spot type 2 diabetes early, especially in people who may not have easy access to care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.